Diagnostic value of serum levels of interleukin-9,interleukin-18 and interleukin-32 in patients with multiple myeloma

Zhuang Ni-la; Zhan Wen-li; Mo Tai-jin; Li Xiao-gan; Zeng Xiang-xing; Wang Qiu-xiang

doi:10.3969/j.issn.1671-2390.l20-188

Journal of Clinical Nephrology > 2021 > 21(7): 556-561. > DOI: 10.3969/j.issn.1671-2390.l20-188

Zhuang Ni-la, Zhan Wen-li, Mo Tai-jin, Li Xiao-gan, Zeng Xiang-xing, Wang Qiu-xiang. Diagnostic value of serum levels of interleukin-9,interleukin-18 and interleukin-32 in patients with multiple myeloma[J]. Journal of Clinical Nephrology, 2021, 21(7): 556-561. DOI: 10.3969/j.issn.1671-2390.l20-188

Citation:

PDF (948 KB)

Diagnostic value of serum levels of interleukin-9,interleukin-18 and interleukin-32 in patients with multiple myeloma

1. Department of Clinical Laboratory Medicine, Tunchang County People's Hospital of Hainan Province, Tunchang 571600, China;
2. Department of Clinical Laboratory Medicine, Haikou People's Hospital, Haikou 571700, China

More Information

Received Date: August 22, 2020
Available Online: May 11, 2023

Graphical Abstract

Abstract

Abstract

Objective To explore the serum expressions of interleukin-9(IL-9),interleukin-18(IL-18) and interleukin-32(IL-32) in patients with multiple myeloma(MM) and examine their values in predicting renal injury.Methods Seventy-eight MM patients from January 2015 to December 2019 were divided into phase I(n=15),phase II(n=26) and phase III(n=37) according to the International Staging System.Based upon renal function,they were divided into renal injury group(n=28) and renal non-injury group(n=50).Another 50 normal subjects in the same period were selected as control group.The serum levels of IL-9,IL-18,IL-32 and β₂-microglobulin(β₂-MG) were detected in each group.Receiver operating characteristic(ROC) curve was utilized for examining the values of serum levels of IL-9,IL-18,IL-32 and β₂-MG in the diagnosis of renal injury.Pearson's correlation analysis was utilized for examining the correlation between serum levels of IL-9,IL-18,IL-32 and β₂-MG.Results The serum levels of IL-9[(63.15±18.36) ng/L vs (22.78±7.15) ng/L],IL-18[(580.64±70.35) ng/L vs (174.30±26.82) ng/L],IL-32[(817.62±112.36) ng/L vs (260.85±34.70) ng/L]and β₂-MG](6.50±2.52) mg/L vs (1.66±0.58) mg/L]were significantly higher in MM group than those in control group(P<0.001).With the advancing of ISS stage,the serum levels of IL-9,IL-18,IL-32 and β₂-MG spiked in MM patients(P<0.001).The serum levels of IL-9[(91.26±19.42) ng/L vs (45.30±14.20) ng/L],IL-18[(812.46±95.2) ng/L vs (407.28±53.60) ng/L],IL-32[(1130.85±154.70) ng/L vs (604.20±71.38) ng/L]and β₂-MG[(10.18±4.75) mg/L vs (3.15±1.06) mg/L]were significantly higher in renal injury group than those in renal non-injury group(P<0.001).ROC curve analysis revealed that the area under the curve(0.963,95%CI:0.905-0.997) of IL-9,IL-18,IL-32 and β₂-MG combined diagnosis of renal injury in MM was the largest and its sensitivity and specificity were 98.6% and 81.2%.Correlation analysis showed that serum levels of IL-9,IL-18,IL-32 and β₂-MG were positively correlated in MM patients(P<0.001).Conclusion The serum levels of IL-9,IL-18 and IL-32 are significantly elevated in MM patients.Correlated with disease stage and renal injury,combine detection of β₂-MG has an excellent value in the diagnosis of renal injury in MM patients.
- Multiple myeloma,
- Interleukin-9,
- Interleukin-18,
- Interleukin-32,
- Kidney injury

FullText(HTML)

References (20)

References

[1]	Rajkumar SV.Multiple myeloma:2020 update on diagnosis,risk-stratification and management[J].Am J Hematol,2020,95(5):548-567.DOI: 10.1002/ajh.25791.
[2]	Kohsari M,Khadem-Ansari MH,Rasmi Y,et al.Serum levels of interleukin-8 and soluble interleukin-6 receptor in patients with stage-I multiple myeloma:a case-control study[J].Asian Pac J Cancer Prev,2020,21(1):127-132.DOI: 10.31557/APJCP.2020.21.1.127.
[3]	Bonanni V,Antonangeli F,Santoni A,et al.Targeting of CXCR3 improves anti-myeloma efficacy of adoptively transferred activated natural killer cells[J].J Immunother Cancer,2019,7(1):290.DOI: 10.1186/s40425-019-0751-5.
[4]	Zahoor M,Westhrin M,Aass KR,et al.Hypoxia promotes IL-32 expression in myeloma cells,and high expression is associated with poor survival and bone loss[J].Blood Adv,2017,1(27):2656-2666.DOI: 10.1182/bloodadvances.2017010801.
[5]	Shahzad MN,Ijaz I,Naqvi SSZH,et al.Association between interleukin gene polymorphisms and multiple myeloma susceptibility[J].Mol Clin Oncol,2020,12(3):212-224.DOI: 10.3892/mco.2020.1979.
[6]	Maaroufi A,Khadem-Ansari MH,Khalkhali HR,et al.Serum levels of bone sialoprotein,osteopontin,and β2-microglobulin in stage I of multiple myeloma[J].J Cancer Res Ther,2020,16(1):98-101.DOI: 10.4103/jcrt.JCRT_666_16.
[7]	中国医师协会血液科医师分会,中华医学会血液学分会,中国医师协会多发性骨髓瘤专业委员会.中国多发性骨髓瘤诊治指南(2020年修订)[J].中华内科杂志,2020,59(5):341-346.DOI: 10.3760/cma.j.cn112138-20200304-00179. Hematology branch of Chinese Medical Doctor Association,hematology branch of Chinese Medical Association,multiple myeloma Professional Committee of Chinese Medical Doctor Association.The guidelines for the diagnosis and management of multiple myeloma in China(2020 revision)[J].Chin J Intern Med,2020,59(5):341-346.DOI: 10.3760/cma.j.cn112138-20200304-00179.
[8]	Shaikh SP,Irfan SM,Sheikh SS.Disease staging according to international scoring system in newly diagnosed patients with multiple myeloma[J].Pak J Med Sci,2019,35(1):90-94.DOI: 10.12669/pjms.35.1.173.
[9]	姜倩倩,吴小燕,王白莹.多发性骨髓瘤合并肾损伤患者的临床特点及危险因素分析[J].中华肾脏病杂志,2020,36(2):123-130.DOI: 10.3760/cma.j.issn.1001-7097.2020.02.009. Jiang QQ,Wu XY,Wang BY.Clinical characteristics and risk factors of multiple myeloma patients with renal impairment[J].Chin J Nephrol,2020,36(2):123-130.DOI: 10.3760/cma.j.issn.1001-7097.2020.02.009.
[10]	Abbassy HA,Aboelwafa RA,Ghallab OM.Evaluation of interleukin-9 expression as a potential therapeutic target in chronic lymphocytic leukemia in a cohort of Egyptian patients[J].Indian J Hematol Blood Transfus,2017,33(4):477-482.DOI: 10.1007/s12288-017-0804-1.
[11]	Tsirakis G,Roussou P,Pappa CA,et al.Increased serum levels of MIP-1alpha correlate with bone disease and angiogenic cytokines in patients with multiple myeloma[J].Med Oncol,2013,31(1):1-5.DOI: 10.1007/s12032-013-0778-2.
[12]	Lin XR,Yang L,Wang G,et al.Interleukin-32α promotes the proliferation of multiple myeloma cells by inducing production of IL-6 in bone marrow stromal cells[J].Oncotarget,2017,8(54):92841-92854.DOI: 10.18632/oncotarget.21611.
[13]	冶薇,程虹,封敏.血清DKK1、β2-微球蛋白水平与多发性骨髓瘤患病程度的相关性[J].临床输血与检验,2019,21(6):564-567.DOI: 10.3969/j.issn.1671-2587.2019.06.002. Ye W,Cheng H,Feng M.Analysis of association of serum levels of DKK₁ and β2-microglobulin with the progress of multiple myeloma disease[J].J Clin Transfus Lab Med,2019,21(6):564-567.DOI: 10.3969/j.issn.1671-2587.2019.06.002.
[14]	Ma TT,Zhang YC,Zhou X,et al.A unique role of T helper 17 cells in different treatment stages of multiple myeloma[J].Clin Lymphoma Myeloma Leuk,2020,20(3):190-197.DOI: 10.1016/j.clml.2019.12.009.
[15]	Wang G,Ning FY,Wang JH,et al.Expression of interleukin-32 in bone marrow of patients with myeloma and its prognostic significance[J].World J Clin Cases,2019,7(24):4234-4244.DOI: 10.12998/wjcc.v7.i24.4234.
[16]	张蕴玉,彭静,宋志刚,等.胱抑素C与β2-微球蛋白在多发性骨髓瘤病情及近期疗效评估中的应用[J].国际肿瘤学杂志,2019,46(10):590-594.DOI: 10.3760/cma.j.issn.1673-422X.2019.10.004. Zhang YY,Peng J,Song ZG,et al.Application of cystatin C and β2-microglobulin in the assessment of condition and short-term efficacy of multiple myeloma[J].J Int Oncol,2019,46(10):590-594.DOI: 10.3760/cma.j.issn.1673-422X.2019.10.004.
[17]	Chang YL,Xing XL,Jiang Y,et al.Serum interleukin-9 concentration is associated with the hemoglobin level and renal function in patients with multiple myeloma[J].Ann Clin Lab Sci,2019,49(4):513-518.
[18]	Chuang LP,Lin SW,Lee LA,et al.Elevated serum markers of acute kidney injury in patients with obstructive sleep apnea[J].J Clin Sleep Med,2019,15(2):207-213.DOI: 10.5664/jcsm.7618.
[19]	金晓娜,周宝珍,张党锋.多发性骨髓瘤患者VEGF、IL-17、β2-MG、IL-35表达水平及临床意义[J].中国实验血液学杂志,2018,26(1):192-196.DOI: 10.7534/j.issn.1009-2137.2018.01.033. Jin XN,Zhou BZ,Zhang DF.Expression level and clinical significance of VEGF,IL-17,β2-MG and IL-35 in patients with multiple myeloma[J].J Exp Hematol,2018,26(1):192-196.DOI: 10.7534/j.issn.1009-2137.2018.01.033.
[20]	Nakamura K,Kassem S,Cleynen A,et al.Dysregulated IL-18 is a key driver of immunosuppression and a possible therapeutic target in the multiple myeloma microenvironment[J].Cancer Cell,2018,33(4):634-648.e5.DOI: 10.1016/j.ccell.2018.02.007.

[1]	Yang Bi-xia, Zhou Hua, Yang Min. Role of interleukin-36 in kidney disease[J]. Journal of Clinical Nephrology, 2023, 23(11): 951-956. DOI: 10.3969/j.issn.1671-2390.2023.11.011
[2]	Liu Chao, Yu Xiao-yang, Wang Zhi-gang, Zhao Can. Exploratory study of serum IL-36 subfamily as biomarkers of disease progression in lupus nephritis[J]. Journal of Clinical Nephrology, 2023, 23(10): 798-804. DOI: 10.3969/j.issn.1671-2390.2023.10.002
[3]	Wang Li-li, Yang Man-ling, Hou Jing, Wang Li-juan. Efficacy and safety of roxadustat in hemodialysis patients with renal anemia based upon the changes of erythropoietin, interleukin-6 and △Hbmax[J]. Journal of Clinical Nephrology, 2023, 23(5): 357-362. DOI: 10.3969/j.issn.1671-2390.2023.05.002
[4]	Xia Fang, Wan Ya-qin, Hu Long, Xia Qian, Wang Yuan-da, Liu Jin-xia. Protective effect mechanism of artesunate on rat kidney with purpuric nephritis through IL-6/ STAT3 signaling pathway[J]. Journal of Clinical Nephrology, 2022, 22(12): 1030-1035. DOI: 10.3969/j.issn.1671-2390.2022.12.010
[5]	Peng Li, Wang Li, Liu Wei-jia, Pan Chun-qin, Liu Jie. Clinical values of serum interleukin-17A and interleukin-23 in predicting the occurrence and progression of IgA vasculitis nephritis[J]. Journal of Clinical Nephrology, 2022, 22(10): 793-799. DOI: 10.3969/j.issn.1671-2390.2022.10.001
[6]	Zhao Dan, Zhu Xiao-yu, Jiang Li-li, Wei Xue-jiao, Long Meng-tuan, Jin Die, Miao Changxiu, Du Yu-jun. Research advances in understanding the role of interleukin-22 in renal disease[J]. Journal of Clinical Nephrology, 2022, 22(1): 58-62. DOI: 10.3969/j.issn.1671-2390.2022.01.011
[7]	Pang Hao-wen, An Ning, Yang Chen, Liu Hua-feng. Research advances in functional roles of Th17 and IL-17 in acute kidney injury[J]. Journal of Clinical Nephrology, 2021, 21(11): 944-950. DOI: 10.3969/j.issn.1671-2390.2021.11.011
[8]	Mo Li-wen, Ning Jiao-lin, Zhang Fan, Lai Xi-nan. Effects of hydrogen sulfide on kidney injury after extremity explosion injury in rats[J]. Journal of Clinical Nephrology, 2021, 21(9): 755-760. DOI: 10.3969/j.issn.1671-2390.2021.09.010
[9]	Yang Fan, Bao Yu-shi. Research advances of interleukin-6 in peritoneal dialysis-related complications[J]. Journal of Clinical Nephrology, 2021, 21(6): 512-515. DOI: 10.3969/j.issn.1671-2390.y20-224
[10]	CHEN Lin-zhou, PENG Wei-hua, XU Min-min, PENG Ting, ZHUANG Yong-ze, WANG Li-ping, YU Guo-qing. Expression of interleukin-18 in patients with renal damage induced by ANCA-associated small vasculitis and its clinical significance[J]. Journal of Clinical Nephrology, 2018, 18(10): 593-597. DOI: 10.3969/j.issn.1671-2390.2018.10.002

Cited By

Cited by

Periodical cited type(8)

1.	张微娟，于静，邓华丽. 多发性骨髓瘤患者并发肾损伤logistic回归分析. 慢性病学杂志. 2025(02): 181-184 .
2.	李辉锋，丁琪，毛永炎. 血清β_2-MG、IL-17、FLC联合检测对多发性骨髓瘤早期肾损伤的诊断价值分析. 实用癌症杂志. 2024(05): 781-784 .
3.	马丽媛，于小汇，张宁宇. 多发性骨髓瘤手术治疗患者外周血细胞积分和IL-32与预后的关系. 检验医学. 2024(05): 458-463 .
4.	沈佳坤，郑林，董慧娟，颜静秀. 多发性骨髓瘤患者血清IL-32、IL-37、sIL-2R水平及临床意义. 实用中西医结合临床. 2024(13): 92-95 .
5.	沈佳坤，董慧娟，郑林，颜静秀. 急性白血病患者血清TK1、IL-32、TNF-α水平及临床意义. 现代诊断与治疗. 2024(15): 2333-2334+2337 .
6.	姜铭，徐娟，丁林林，贲海祥，尹红. 血清IL-32 sRAGE及NLR与多发性骨髓瘤合并肾损伤的相关性分析. 河北医学. 2023(08): 1279-1283 .
7.	贾雁文. 血清学指标检测在多发性骨髓瘤患者肾损伤诊断中的应用价值. 实用检验医师杂志. 2023(03): 246-249 .
8.	张琦，田朝霞，佟明铭，李坤，陶红. 胰炎消方对重症急性胰腺炎患者miR21-3p、IL-18及肾功能相关指标的影响. 中国中医急症. 2022(10): 1776-1779 .

Other cited types(0)

Get Citation

PDF

XML

Article views (270) PDF downloads (186) Cited by(8)

Turn off MathJax

Article Contents

Abstract

References

Diagnostic value of serum levels of interleukin-9,interleukin-18 and interleukin-32 in patients with multiple myeloma

Abstract

References

Related Articles

Cited by

Periodical cited type(8)

Other cited types(0)

Catalog

Diagnostic value of serum levels of interleukin-9,interleukin-18 and interleukin-32 in patients with multiple myeloma

Abstract

References

Related Articles

Cited by

Periodical cited type(8)

Other cited types(0)

Catalog

Export File

Citation

Format

Content